HSIC vs RGNX · P/E 24, rev $6.83B vs rev $114.4M
Henry Schein Inc (HSIC) versus Regenxbio Inc (RGNX) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. RGNX currently screens at market cap $440.4M.
Not investment advice. Open the HSIC and RGNX stock pages for the full models.
Not investment advice.